October 24th 2024
Nina Vadiei, PharmD, BCPP, a clinical associate professor at UT Austin and a clinical pharmacy specialist in psychiatry at San Antonio State Hospital, discusses her career as a psychiatric pharmacist.
Eli Lilly to pay more than $800 million for off-label promotion of Zyprexa
January 20th 2009Eli Lilly and Co. has agreed to plead guilty to one misdemeanor violation of the Food, Drug, and Cosmetic Act and will pay more approximately $800 million for unproven marketing and promotional claims involving the antipsychotic medication Zyprexa.
IV drug errors highlight need for universal standards
January 1st 2009The annual summit of the American Society of Health-System Pharmacists called for ways to reduce drug errors. The need for universal IV concentrations is primary. "Safety will improve dramatically if we all work with the same tools." (Peter Angood, Joint Commission)
Report: Pharmacies must do more to stop drug diversions
December 30th 2008A recent report by the Coalition Against Insurance Fraud suggests pharmacies and pharmacy regulators need better training and education to help prevent prescription drug diversion, particularly of controlled substance analgesics.
UCSF investigators: Drug companies distort trial information
December 17th 2008A team of medical investigators at the University of California, San Francisco, has accused drug companies of bias by distorting the results of their trials in medical journals, which many doctors rely on to determine whether to prescribe new drugs.
FDA recalls unapproved devices
December 16th 2008The U.S. Food and Drug Administration recently recalled two unapproved and uncleared devices whose manufacturers claimed could treat various medical conditions. The recall was a Class 1, which means there is a reasonable probability that the use of a device will cause adverse reactions, including death.